Related Experiment Videos
[Platelet antiaggregants]
1Service de Biochimie médicale Cliniques Universitaires St-Luc, Bruxelles, Belgique.
Insights
Acetylsalicylic acid is a highly effective antiplatelet agent for preventing thromboses, particularly those linked to atherosclerosis. Current evidence suggests combination therapies do not offer superior benefits over aspirin alone.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
Context:
- Atherosclerosis is a leading cause of thrombotic events.
- Antiplatelet therapy is crucial for secondary prevention.
Purpose:
- To review the efficacy and usage of antiplatelet agents.
- To compare combination therapies with monotherapy.
Summary:
- Acetylsalicylic acid (aspirin) is the primary antiplatelet agent, with a recommended dose of 300 mg daily.
- Ticlopidine and dipyridamole are alternatives but have more contraindications.
- Clinical studies indicate no added benefit of combining antiplatelet agents over aspirin monotherapy.
Impact:
- Provides guidance on optimal antiplatelet selection and dosage.
- Highlights limitations and contraindications of certain agents.
- Supports the continued use of aspirin as a cornerstone therapy.
Abstract:
Antiplatelet agents are indicated in the prophylactic treatment of certain thromboses, and in particular those due to a complication of atherosclerosis. Acetylsalicylic acid is the best-known, the most commonly used and, probably, the currently most effective agent. The dosage remains controversial; yet, a mean dose of 300 mg daily appears to be recommended nowadays. Ticlopidine and, to a lesser extent, dipyridamole can also be used for this treatment. However numerous contra-indications, such as haemorragic diathesis, surgery and gastric ulcers tend to limit their use. As regards the combination of antiplatelet agents, clinical studies do not show superior efficacy as compared with acetylsalicyclic acid alone.